Clinical trial · Interventional
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
NCT00884520CI-TRIAL-00003262VM4-037completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design: Exploratory, open label, nonrandomized, multi-center study Duration: Three visits - one screening, one imaging, and one follow-up visit at 24 hours post-dose Procedures: Informed consent, collection of demographic information and medical history, physical examinations, vital signs, 12-lead ECGs, routine blood tests to assess major organ functions, complete blood counts and clinical chemistries for safety, blood sample for CA-IX assay, pre-dose and post-dose blood samples for metabolite analysis, dosing with \[F-18\]VM4-037, PET imaging scan, dosimetry estimation (normals), urine collections (normals), tumor immunohistochemistry with CA-IX biomarker, follow up to imaging to collect adverse events Subjects: Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head \& neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Hepatic Carcinoma | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Squamous Cell Carcinoma | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [F-18] VM4-037 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VM4-037
- description
- Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head \& neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
- interventionNames
- Drug: [F-18] VM4-037
Primary outcomes (1)
- measure
- Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.
- timeFrame
- (3) study visits, including the initial screening visit, the imaging visit, and the 24 hour follow-up visit
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Normal Volunteers * Subject is ≥ 18 years old at the time of investigational product administration, and subject is male or female of any race / ethnicity * Subject or subject's legally acceptable representative provides written informed consent * Subject is capable of complying with study procedures * Subject is capable of communicating with study personnel * Subject must have renal and hepatic functions and haematological values as defined by laboratory results within defined ranges Cancer Subjects * Subject is ≥ 18 years old at the time of the investigational product administration, and subject is a male or female of any race/ethnicity * Subject or subject's legally acceptable representative provides written informed consent * Subject is capable of complying with study procedures * Subject is capable of communicating with study personnel * Subject must have renal and hepatic functions and haematological values as defined by laboratory results within defined ranges * Subject must have confirmed or highly suspected non-small cell lung cancer (local or with metastases), squamous cell carcinoma (advanced stages) of the head and neck whose primary origin was from oral cavity, oropharynx, hypopharynx or larynx (local or with metastases), large solitary hepatic carcinoma (primary or metastatic), or renal cell carcinoma (local or with metastases ) * Subject has an adequate size of tumors (≥2 cm) that should be amenable to imaging and biopsy for immunohistochemistry assay using CA-IX and/or hypoxia biomarkers * Subject did not have any anticancer treatment intervention between \[F-18\]VM4-037 scan and sampling of biopsied tissue * Subject is scheduled for a clinical \[F-18\]FDG PET scan within 14 days either prior to or after the investigational, \[F-18\]VM4-037 scan (with no anticancer treatment interventions between the two PET scans) * Subject has a value of ≥ 60% at the time screening according to the Karnofsky Performance Status Scale Exclusion Criteria: Normal Volunteers * Subject is \< 18 years old at the time of investigational product administration * Subject is nursing * Female subject is pregnant * Subject is unable to remain still for duration of imaging procedure * Subject has a significant hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by above lab tests in inclusion criteria * Subject has previously received \[F-18\]VM4-037 at any time * Subject has been involved in an investigative, radioactive research procedure within the past 14 days * Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality * Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives Cancer Subjects * Subject is \< 18 years old at the time of investigational product administration * Subject is nursing * Female subject is pregnant * Subject is unable to remain still for duration of imaging procedure * Subject has significant hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by above lab tests in inclusion criteria * Subject has previously received \[F-18\]VM4-037 at any time * Subject has been involved in an investigative, radioactive research procedure within the past 14 days * Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data or data quality * Subject has a history of significant prescription or non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives * Subject has had an anticancer treatment intervention between \[F-18\]VM4-037 scan and biopsied tissue sampling * Subject has had an anticancer treatment intervention between \[F-18\]VM4-037 scan and \[F-18\]FDG scan * Subject has an inadequate tumor sites or volume (\< 2 cm) to allow for PET images and biopsy for immunohistochemistry
References
Publications (1)
- DERIVEDDoss M, Kolb HC, Walsh JC, Mocharla VP, Zhu Z, Haka M, Alpaugh RK, Chen DY, Yu JQ. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers. Mol Imaging Biol. 2014 Oct;16(5):739-46. doi: 10.1007/s11307-014-0730-7. PMID 24696183